Search
× Search

Peak Flow Monitoring

What is peak flow?

Peak flow is the measurement of how effectively air moves out of your lungs . A peak flow meter monitors your asthma the way a blood pressure cuff monitors your blood pressure. Measuring peak flow helps determine any narrowing in your airways before you have an actual attack. This allows you to take your medicine before a serious attack develops.

Why is peak flow monitoring so important?

Peak flow monitoring allows you and your doctor to manage your condition effectively. It gives an accurate picture of your condition that allows your doctor to make appropriate decisions regarding the effectiveness of your medicine plan and treatment plan .

Other benefits of peak flow monitoring include the following:

  • Helps you decide whether your condition is serious enough to seek emergency treatment.
  • Allows you to detect early stages of airway obstruction to start immediate treatment.
  • Gives you an accurate picture of the variations in your condition over a 24- hour period. This permits your doctor to prescribe treatment when you need it the most.
  • Helps you differentiate between airway obstruction and other causes of breathlessness like hyperventilation.
  • Allows you to ascertain specific allergens, irritants, or workplace exposures that may cause your symptoms to develop.
  • Enables you to communicate more effectively with your doctor so that he or she can provide guidance over the phone if needed.
  • May be an effective detector to monitor whether your asthma symptoms have stabilized, improved, or deteriorated/worsened.

How do I start?

Most adults and young children can use a peak flow meter.

All it requires is a short, hard blow of air into the meter. Here's how to use the peak flow meter :

  • Place the indicator at the base of the numbered scale.
  • Sit upright or stand up.
  • Take a deep breath .
  • Place the meter in your mouth and close your lips around the mouthpiece. Be sure not to put your tongue in the hole.
  • Blow out as hard and fast as you can.
  • Write down the number that you get.
  • Repeat the above steps two more times.
  • Write down the highest of the three numbers in your asthma diary.

What is the "Three Zone" system?

You need to find your personal best peak flow number. This is the highest number that you can attain over a 2-week period when you feel good and do not have any asthma symptoms. These measurements should be taken when you wake up and in the evening. They should also be taken before and after taking an inhaled medication , if you use one. Keep an accurate record of these readings so that you can discuss them with your doctor.

Peak flow numbers have been put into zones that are set up like a traffic light. Using your personal best peak flow number, you can determine what zone the reading falls in and respond with the appropriate treatment.

For example:

traffic signal with red, yellow, and green lights

GREEN ZONE (80% to 100% of your personal
best number)

The green zone signals all clear. No asthma symptoms are present and you can take your medications as you have been doing.

YELLOW ZONE (50% to 8O% of your personal best number)

The yellow zone signals caution. You may be having an asthma attack that requires an increase in medication, or your doctor may need to change your treatment plan because your asthma is not under control.

RED ZONE (below 50% of your
personal best number)

The red zone signals a medical alert. You should first take your short-acting bronchodilator immediately and then contact your doctor right away.

Be sure to talk to your doctor regarding peak flow monitoring. Your particular zones should be established based on your individual condition.

How do I keep track of my peak flow readings?

It is important to keep a daily diary of your peak flow readings so that you and your doctor can better evaluate your treatment plan . This information can help you to effectively control your condition and lead a more active, healthy life.

Recent News

SuperUser Account
/ Categories: News

American College of Allergy, Asthma, and Immunology (ACAAI) Guidance on Risk of Allergic Reactions to the Pfizer-BioNTech COVID-19 Vaccine

Allergic reactions to vaccines, in general, are rare with the incidence of anaphylaxis estimated at 1.31 in 1 million doses given. With the emergency use authorization of the Pfizer-BioNTech COVID-19 vaccine by the FDA on December 11, 2020, the ACAAI COVID-19 Vaccine Task Force recommends the following guidance for physicians and other providers related to risk of an allergic reaction on vaccination. These recommendations are based on best knowledge to date but could change at any time, pending new information and further guidance from the FDA or CDC. 
 
1. The Pfizer-BioNTech COVID-19 vaccine should be administered in a health care setting where anaphylaxis can be treated. All individuals must be observed for at least 20-30 minutes after injection to monitor for any adverse reaction. All anaphylactic reactions should be managed immediately with IM epinephrine as the first line treatment.
 
2. The Pfizer-BioNTech COVID-19 vaccine should not be administered to individuals with a known history of a severe allergic reaction to polyethylene glycol as it is a component of this vaccine known to cause anaphylaxis.
 
3. Data related to risk in individuals with a history of allergic reactions to previous vaccinations and/or mast cell activation syndrome/idiopathic anaphylaxis is very limited and evolving. A clinical decision to administer the Pfizer-BioNTech COVID-19 vaccine should be undertaken by the physician or other provider administering the vaccine using their professional judgment and in consultation with the patient, balancing the benefits and risks associated with taking the vaccine.
 
4. Individuals with common allergies to medications, foods, inhalants, insects and latex are no more likely than the general public to have an allergic reaction to the Pfizer-BioNTech COVID-19 vaccine. Those patients should be informed of the benefits of the vaccine versus its risks.
 
5. The Pfizer-BioNTech COVID-19 vaccine is not a live vaccine and can be administered to immunocompromised patients. Physicians and other providers should inform such immunocompromised patients of the possibility of a diminished immune response to the vaccine.
 
6. Anyone with questions related to the risk of an allergic reaction to the Pfizer-BioNTech COVID-19 vaccine should contact their local board-certified allergist/immunologist.
 
 
References
 
McNeil MM, Weintraub ES, Duffy J, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016;137(3):868-878.
 
Dreskin et al. International Consensus (ICON): allergic reactions to vaccines
World Allergy Organization Journal (2016) 9:32.
 
Wylon, K., Dölle, S. & Worm, M. Polyethylene glycol as a cause of anaphylaxis. Allergy Asthma Clin Immunol 12, 67 (2016).

Stone CA, Liu Y, et al. Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized.  J Allergy Clin Immunol Pract. 2019; 7(5): 1533–1540.

The post American College of Allergy, Asthma, and Immunology (ACAAI) Guidance on Risk of Allergic Reactions to the Pfizer-BioNTech COVID-19 Vaccine appeared first on Oklahoma Allergy and Asthma Clinic.

Previous Article REAL-WORLD PRESCHOOL PEANUT ORAL IMMUNOTHERAPY EFFECTIVE AFTER ONE YEAR OF MAINTENANCE
Next Article FDA COVID-19 vaccines information website link
Print
87
Terms Of UsePrivacy StatementCopyright 2026 by Oklahoma Allergy and Asthma Clinic
Back To Top